TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's
LONDON TauRx Therapeutics Ltd. announced the start of a 180-patient Phase III trial of its tau aggregation inhibitor, LMTX, in Pick's disease, an early onset form of dementia that shows similar characteristics to Alzheimer's disease.
The study in Pick's, or behavioral-variant frontotemporal dementia (bvFTD), is due to be followed by a Phase III trial of LMTX in Alzheimer's. Funding for both trials is in place.
Suite: 1100 | Atlanta, Georgia 30346, USA
Tel: +1 877.857.2477
Outside of the US
Tel. +44 203 684 1796
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter